EAM
Erste Asset Management Portfolio holdings
AUM
$11.9B
1-Year Return
22.95%
This Quarter Return
-1.24%
1 Year Return
+22.95%
3 Year Return
+112.82%
5 Year Return
+205.55%
10 Year Return
–
AUM
$5.05B
AUM Growth
+$28.3M
(+0.56%)
Cap. Flow
+$164M
Cap. Flow
% of AUM
3.25%
Top 10 Holdings %
Top 10 Hldgs %
19.52%
Holding
911
New
26
Increased
159
Reduced
108
Closed
21
Top Buys
| 1 |
Victoria's Secret
VSCO
|
+$33.2M |
| 2 |
Moderna
MRNA
|
+$22.6M |
| 3 |
Marsh & McLennan
MMC
|
+$19.8M |
| 4 |
Automatic Data Processing
ADP
|
+$19.3M |
| 5 |
Costco
COST
|
+$16.6M |
Top Sells
| 1 |
Oracle
ORCL
|
+$19.8M |
| 2 |
Bath & Body Works
BBWI
|
+$18.2M |
| 3 |
Ametek
AME
|
+$13.5M |
| 4 |
NextEra Energy, Inc.
NEE
|
+$12.7M |
| 5 |
Signet Jewelers
SIG
|
+$11.8M |
Sector Composition
| 1 | Technology | 29.95% |
| 2 | Healthcare | 19.46% |
| 3 | Consumer Discretionary | 13.98% |
| 4 | Financials | 9.64% |
| 5 | Industrials | 7.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Western Union
WU
$2.82B
| $1.07M | 0.02% |
51,400
| – | – |
|
327
Idexx Laboratories
IDXX
$52.2B
| $1.06M | 0.02% |
1,695
+795
| +88% | +$499K |
|
328
Wells Fargo
WFC
$254B
| $1.06M | 0.02% |
22,581
+1,253
| +6% | +$58.9K |
|
329
Allogene Therapeutics
ALLO
$253M
| $1.05M | 0.02% |
40,800
| – | – |
|
330
Fate Therapeutics
FATE
$111M
| $1.03M | 0.02% |
17,200
| – | – |
|
|
AMRN
331
Amarin Corp
AMRN
$306M
| $1.02M | 0.02% |
9,900
| – | – |
|
332
GeoPark
GPRK
$317M
| $988K | 0.02% |
80,000
| – | – |
|
333
Goldman Sachs
GS
$225B
| $977K | 0.02% |
2,539
+141
| +6% | +$54.3K |
|
334
Ocular Therapeutix
OCUL
$2.21B
| $971K | 0.02% |
95,800
+26,000
| +37% | +$264K |
|
|
B
335
Barrick Mining Corporation
B
$49.5B
| $967K | 0.02% |
53,600
-830
| -2% | -$15K |
|
336
Cheniere Energy
LNG
$51.3B
| $908K | 0.02% |
9,300
| – | – |
|
|
337
Ametek
AME
$43.6B
| $893K | 0.02% |
7,052
-106,439
| -94% | -$13.5M |
|
338
Canadian Natural Resources
CNQ
$63B
| $877K | 0.02% |
49,008
+38,798
| +380% | +$694K |
|
339
Kinder Morgan
KMI
$58.8B
| $860K | 0.02% |
50,800
| – | – |
|
340
Travere Therapeutics
TVTX
$1.89B
| $854K | 0.02% |
35,600
| – | – |
|
341
Hartford Financial Services
HIG
$36.7B
| $846K | 0.02% |
11,800
| – | – |
|
342
Analog Devices
ADI
$122B
| $844K | 0.02% |
5,000
| – | – |
|
|
KRTX
343
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $840K | 0.02% |
7,070
| – | – |
|
344
Nektar Therapeutics
NKTR
$843M
| $839K | 0.02% |
3,120
| – | – |
|
345
Freeport-McMoran
FCX
$67B
| $838K | 0.02% |
25,400
| – | – |
|
346
Arch Capital
ACGL
$33.9B
| $835K | 0.02% |
21,500
| – | – |
|
347
Pacira BioSciences
PCRX
$1.2B
| $817K | 0.02% |
14,400
| – | – |
|
348
Editas Medicine
EDIT
$251M
| $808K | 0.02% |
19,000
| – | – |
|
349
GE Aerospace
GE
$293B
| $780K | 0.02% |
11,781
+641
| +6% | +$42.4K |
|
350
Bilibili
BILI
$9.31B
| $773K | 0.02% |
12,000
| – | – |
|